Twinhale · In silico trials for pulmonary drug delivery with breakthrough digital twins of the lungs

Due to the limitedness of current technologies, the respiratory system has historically been a sort of black box in many aspects of R&D and clinical practice. At Ebenbuild we want to open this black box by building the first accurate, patient-specific simulation models of the lungs, the so-called digital twins of the lungs. In addition to patient data, these are based on first-of-a-kind predictive, physiologically accurate computational models of the respiratory system. By opening the black box for the very first time, our technology holds the potential to become the definitive source of health intelligence for respiratory diseases across a variety of use cases in healthcare and life sciences, from preclinical R&D to point-of-care. This will make Ebenbuild a deep-tech vanguard with a diversified spectrum of scalable products, each with a significant patient benefit and a global revenue potential and with our technological platform at their core.With EIC support we aim at expanding and validating the potential of our technology for provision of Twinhale tool to Biotech, MedTech and Pharma companies. Twinhale supports in-silico trials for pulmonary drug delivery and enables faster development of better inhalable treatments. Achieving this milestone will not only unlock an intriguing business opportunity, but will also be the starting point to further develop and eventually position our platform products along the entire spectrum of the medical value chain, from the inception of novel therapies to their application at the point-of-care.